Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label Study to Investigate the Tolerability and Safety of IBI310 Alone or in Combination With Sintilimab in the Treatment of Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I, Open-Label Study to Investigate the Tolerability and Safety of IBI310 Alone or in Combination With Sintilimab in the Treatment of Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Sintilimab (Primary)
  • Indications Acral lentiginous melanoma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Innovent Biologics

Most Recent Events

  • 21 Sep 2021 Updated results (n=44; As of April 14, 2021) assessing safety and efficacy of IBI310 alone or in combination with sintilimab in patients with advanced melanoma, presented at the 46th European Society for Medical Oncology Congress.
  • 29 Aug 2021 According to an Innovent Biologics media release, data will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021.
  • 02 Jun 2020 According to an Innovent Biologics media release, preliminary results (as of 12th Nov 2019, n=10 in Phase 1a study and n=17 subjects in Phase 1b study) were announced in the form of online publication at the 56th American Society of Clinical Oncology (ASCO) Annual Meeting. (Online publication, Abstract # 302489).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top